Walkthrough: Design a Continuous Pharmaceutical Manufacturing Facility (Small-Molecule API + Oral Solid Dose)
This walkthrough scopes an end-to-end continuous manufacturing (CMfg) facility for small-molecule API and oral solid dose (OSD) tablets — an integrated train running from reactant feed to finished, packaged tablets in a single, steady-state process with no batch breaks. Reference programs (the 9 FDA-approved CMfg products as of late 2024): Vertex Orkambi / Symdeko / Trikafta (continuous OSD, Boston + Milton Park UK), J&J Janssen Prezista (darunavir) — the first CMfg approval (Apr 2016), Janssen Symtuza, Eli Lilly Verzenio (abemaciclib) + Tauvid + post-2024 expansions, Pfizer Daurismo (glasdegib), Codiak exoIL-12 (manufactured continuous), Merck Vaxneuvance-related elements, Genentech ongoing pilot pipeline.
The continuous-mfg shift has been driven by FDA Modernization commitments since 2015 (CDER’s Emerging Technology Program); EMA + PMDA + Health Canada all encourage CMfg in parallel guidance; ICH Q13 (continuous manufacturing of drug substances and drug products) finalized 2023 provides the harmonized regulatory framework. Capex $100-300M for a multi-product CMfg facility; opex 30-50% reduction vs equivalent batch on labor + footprint + work-in-process inventory + COGS over the product lifecycle.
1. Program spec
| Parameter | Target | Notes |
|---|---|---|
| Modality | Small-molecule API + OSD tablets (immediate-release + film-coated) | Hybrid CMfg supports continuous reactant feed to tablet packaging |
| Output | 1-3 tonnes API/yr → ~50-150M tablets/yr (depending on dose strength) | Multi-product, fast changeover |
| Process steps integrated | Reaction → workup (extraction + crystallization) → filtration → drying → granulation → tablet compression → coating → packaging | Single train, indirect/closed transfer between unit ops |
| Modality (batch vs continuous) | Continuous + RTRT (real-time release testing) | Eliminates intermediate batch holds + reduces COGS |
| Quality framework | ICH Q8/Q9/Q10/Q11/Q12/Q13 + FDA Quality Considerations 2024 | QbD design space + control strategy |
| Regulatory pathway | NDA + sNDA with CMfg-specific module sections (Q13 alignment) | Pre-approval inspection (PAI) for CMfg-specific elements |
| Facility size | 8,000-15,000 m² building including utilities + warehousing | Smaller footprint than batch (40-60%) |
| Capex (greenfield) | $100-300M | Process equipment + facility + qualification |
| Opex savings vs batch | 30-50% per unit | Labor + WIP + footprint + cycle time |
2. Why continuous? Comparison to batch
| Dimension | Batch | Continuous (CMfg) |
|---|---|---|
| Scale-up | Linear vs equipment size — 1L → 100L → 10,000L | ”Scale-out” by run-time at constant equipment scale |
| Footprint | Large (vessels, dryers, transfer rooms) | Compact (40-60% smaller) |
| WIP inventory | High (intermediate holds between unit ops) | Near-zero (in-flight inventory only) |
| Cycle time | Days-weeks API + days OSD | Hours-days end-to-end |
| Process control | End-of-batch sampling | Real-time PAT + multivariate control |
| Quality assurance | Release at QC lab | RTRT (Real-Time Release Testing) via PAT |
| Demand response | Step-change (cancel/restart batch) | Throttle continuous rate |
| Yield (typical) | 60-75% overall | 75-90% (less material loss in transfers, optimized residence time) |
| Cleaning + changeover | Long (CIP + verification between batches) | Optimized; campaign-mode supports multi-product |
| Capex | Established cost-curve | First-of-a-kind premium; ~20-40% higher than equivalent batch capacity but offset by smaller scale required |
| Regulatory | Familiar | ICH Q13 + jurisdiction-specific guidance, but established pathway 2016+ |
3. Continuous API train (drug substance)
3.1 Continuous reactor architecture
Multiple reactor topologies, selected by reaction chemistry:
- PFR (Plug-Flow Reactor) — narrow tube/microreactor; residence time = volume/flow rate; ideal for fast, exothermic, single-phase reactions
- CSTR cascade (3-5 stages) — mimics PFR via series of stirred tanks; better for slower reactions + multiphase + slurry handling
- Tubular + static mixer — typical for 1-2 second residence time + rapid mixing
- Loop reactor + microreactor + structured packed-bed — heterogeneous catalysis, photocatalysis
Vendors:
- Corning Advanced-Flow Reactor (AFR) — glass + silicon-carbide modular flow plates; G1/G3/G4 scales (lab → production); ~$0.3-2M per reactor train
- Chemtrix (Geleen NL) — borosilicate-glass + ceramic microreactors; Plantrix MR family; KiloFlow + LabTrix for development
- Vapourtec (UK) — R-series + E-series flow reactors; pharma + academic workflow
- Syrris (UK, now Asahi Glassplant) — Asia + Atlas + Titan flow systems
- ThalesNano (Hungary) — H-Cube hydrogenation + Phoenix flame + IceCube cryogenic; $80-300K range
- Ehrfeld Mikrotechnik (Wendelsheim DE) — modular microreactors
- AM Technology (UK) — Coflore agitated cell reactor (ACR)
- Zaiput (Cambridge MA) — continuous liquid-liquid separators
- Mettler Toledo — ReactIR + EasyMax + OptiMax (semi-batch but feeds continuous workup)
3.2 Continuous crystallization
Crystallization is the typical workhorse purification step; continuous crystallization is one of the more difficult unit ops:
- MSMPR (Mixed-Suspension Mixed-Product-Removal) — single or cascaded CSTRs operating at steady state; widely deployed
- PFC (Plug-Flow Crystallizer) — tubular flow with controlled cooling/anti-solvent profile
- COBC (Continuous Oscillatory Baffled Crystallizer) — Cambridge spinout NiTech Solutions; oscillatory flow in baffled tube; well-defined residence time + plug-flow behavior in a slurry
- Continuous OBR (Oscillatory Baffled Reactor) — at NiTech (Alconbury UK) and Heriot-Watt Edinburgh (spinout)
- Anti-solvent + cooling combined — for poorly water-soluble APIs
- Seeded vs unseeded — seeded preferred for polymorph control
Real-time monitoring of crystallization: FBRM (Focused Beam Reflectance Measurement, Mettler Toledo), PVM (Particle Vision Measurement), in-line Raman (Kaiser/Endress+Hauser) for polymorph identification, in-line PSD (Sympatec QicPic).
3.3 Continuous filtration
- Continuous rotary vacuum filtration — large-scale, well-established; BHS Sonthofen + Filtres Philippe + ANDRITZ; expensive at small scale
- Continuous filter cake (CFC) — emerging; BHS rotary pressure filter (RPF) family
- Cross-flow MF/UF — for slurries with fine + sticky solids; Pall + Sartorius + Sefiltra + KOCH
- CCF (Cake-Cleaning Filter) — DD-style continuous nutsche filter; CDC International
- Continuous Steady-State Filtration & Drying (CFD) — Alconbury / NiTech / Heriot-Watt integrated unit; small footprint
3.4 Continuous drying
- Plug-flow dryer (PFD) — conveyor + screw + vibratory; controlled residence time
- Spray drying — atomized solution + hot drying gas; widely used; GEA Niro + ProCepT + Büchi (development scale)
- Fluid-bed drying — air-suspended particle drying; GEA ProCell + Glatt
- Vacuum belt dryer — temperature-sensitive APIs; Bucher Unipektin
- Through-air dryer — granules + tablets feed
- Microwave + RF-assisted drying — emerging
Major vendors of integrated CMfg lines: GEA ConsiGma 25/250 (continuous tablet manufacturing line; granulation + drying + milling + tablet press integrated), Glatt MODCOS (continuous granulator + dryer), Bosch (now Syntegon) Xelum, LB Bohle QbCon (containment + continuous), IMA Continua / Kilian (tablet compression integrated).
4. Continuous OSD (drug product)
4.1 Twin-screw granulation
Twin-screw wet granulation (TSWG) replaces the batch high-shear granulator:
- GEA ConsiGma 25 — fully integrated TSWG + fluid-bed drying + milling + blending + tablet compression in one line; ~20-100 kg/h capacity
- GEA ConsiGma 250 — 100-250 kg/h
- Glatt MODCOS — modular continuous system; similar capacity
- Diosna P/VAC — continuous granulator integrated with fluid-bed
- Pharmatech Powderlink — feeding + screw granulation
- K-Tron / Coperion — twin-screw feeders + extruders (loss-in-weight feeders, key for accurate continuous dosing)
4.2 Tablet compression
- Korsch XL 200/400 + XM12 + XP1 — modular high-speed tablet presses
- Fette FE55 + FE75 + FE Compactor 3090i — high-speed rotary presses (up to 1.6M tablets/h)
- IMA Kilian Komtronic + Stylcam — fully integrated with continuous granulator
- Manesty / Bosch Beta / Patheon — long-established rotary press platforms
- Romaco Kilian + Noack — mid-range continuous-compatible
Tablet press at continuous-mfg integration includes:
- Force control on each station (real-time individual tablet weight + hardness)
- Automated reject + sample diversion
- PAT-integrated weight/hardness/thickness feedback (Erweka or Sotax inline tablet testers)
4.3 Tablet coating
- O’Hara Labcoat + Premiercoat + IBC — film-coating systems
- Bohle BFC + BTC — continuous + perforated drum coaters
- GEA ConsiGma Coater — fully integrated continuous coater
- Vector / Freund Hi-Coater + Lab-Coat — pan coaters
- Glatt GC-Continuous — continuous coater + drying
5. PAT — Process Analytical Technology
PAT is the foundational enabling technology for CMfg + RTRT. The 2004 FDA PAT guidance + ICH Q8 + ASTM E2476 frame “design, analyze, and control manufacturing through timely measurements of critical quality and performance attributes of raw and in-process materials and processes, with the goal of ensuring final product quality.”
5.1 In-line + on-line PAT sensors
| Technique | Measurement | Vendor |
|---|---|---|
| NIR (Near-Infrared) | Composition, moisture, blend homogeneity, polymorph (often) | Bruker MPA-II + Matrix-F, Thermo Antaris + Indico, Spectra Analysis EDX, Sentronic SENTRO |
| Raman | Identification + polymorph + API content | Kaiser RamanRxn (now Endress+Hauser), Tornado HyperFlux, B&W TEK i-Raman, Mettler Toledo ReactRaman |
| FT-IR / mid-IR (ATR) | Reaction conversion + intermediate identification | Mettler Toledo ReactIR 15/45m, Bruker ALPHA + MATRIX, Specac |
| UV-Vis | Concentration + impurity (chromophores) | Ocean Optics + ABB FT-NIR |
| LIF (Laser-Induced Fluorescence) | Trace impurity, blend uniformity | Custom + Photon Etc |
| Acoustic emission | Granulation endpoint + tablet ejection force | Sensata + Brüel & Kjær + custom |
| Inline PSD (Particle Size) | Crystals + granules + tablets | Sympatec QicPic (image analysis), Malvern Insitec / Spraytec / Mastersizer 3000, Microtrac S3500 + SyncFiber, Beckman Coulter LS, Retsch Camsizer |
| Capacitance + tribo-electric | Moisture + powder flow | Endress+Hauser + Krohne |
| Image analysis (machine vision) | Tablet defects + coating uniformity | Cognex In-Sight + Keyence CV-X + Sick Vision |
| FBRM + PVM | Crystallization + slurry monitoring | Mettler Toledo ParticleTrack G400 + ParticleView V19 |
5.2 Multivariate modeling + control
PAT spectra fed into multivariate calibration models:
- PLS (Partial Least Squares) — most common; concentration + spectral input
- PCA (Principal Component Analysis) — process fingerprint + outlier detection
- KNN (K-Nearest Neighbors) — classification (polymorph, raw material identity)
- PCR (Principal Component Regression)
- SIMCA (Soft Independent Modeling of Class Analogies)
- Neural networks — emerging for non-linear systems
Software: Umetrics (Sartorius) SIMCA + SIMCA-Q for chemometrics; Camo Analytics Unscrambler; PerkinElmer NIRWare + Spectrum; Eigenvector Research PLS_Toolbox; ProSensus MultiCal.
5.3 RTRT — Real-Time Release Testing
RTRT replaces end-product QC release with model-predicted release based on PAT + in-process measurements. Per ICH Q8(R2):
- Predefined “design space” for CMAs (critical material attributes) + CPPs (critical process parameters)
- Multivariate model predicts CQAs (critical quality attributes) — content uniformity, dissolution, identity, impurities
- “Release in real time” — no QC laboratory hold
FDA + EMA acceptance of RTRT is product-by-product; Vertex’s continuous OSDs were the early case studies. ICH Q13 (2023) formalizes RTRT acceptance criteria.
6. QbD — Quality by Design
6.1 QbD process framework (ICH Q8/Q9/Q10/Q11/Q12/Q13)
- Q8 — Pharmaceutical Development (QbD framework)
- Q9 — Quality Risk Management (FMEA + FMECA + HAZOP)
- Q10 — Pharmaceutical Quality System (PQS)
- Q11 — Development + Manufacture of Drug Substances
- Q12 — Lifecycle Management (Established Conditions, post-approval changes)
- Q13 — Continuous Manufacturing of Drug Substances + Drug Products (2023 final)
QbD process:
- Define QTPP (Quality Target Product Profile) — what the patient needs
- Identify CQAs (Critical Quality Attributes) — measurable properties
- Identify CMAs + CPPs affecting CQAs
- Develop design space — multivariate space of CMAs/CPPs that yields acceptable CQAs
- Establish control strategy — combination of equipment, PAT, models, procedures
- Continual improvement — life-cycle management via Q12 ECs
6.2 QbD-specific data + analytics
- DoE (Design of Experiments) tools: JMP (SAS), Stat-Ease Design-Expert, Modde (Sartorius)
- Process simulation: Aspen Plus + Aspen Properties + gPROMS FormulatedProducts (Siemens) + COCO Simulator + COMSOL Multiphysics; PSE Advanced Process Modelling (now part of Siemens DI)
- DEM (Discrete Element Modeling) for powder flow: EDEM (Altair), Rocky DEM (Ansys), LIGGGHTS (open-source)
- CFD for blending + crystallization: Ansys Fluent + CFX + STAR-CCM+ (Siemens)
- Lifecycle workflow: Veeva Vault QualityDocs + MasterControl + Aras + ETQ + Sparta TrackWise
7. Regulatory pathway
7.1 ICH Q13 + FDA + EMA + PMDA + Health Canada
ICH Q13 (Continuous Manufacturing, final 2023) is the harmonized regulatory framework. Provides:
- Definition + scope (small molecule + biotech)
- Recommendations for control strategy, validation, change management
- Specific guidance on RTRT, batch definition (mass/time or per-run convention), stability program
FDA: CDER Office of Pharmaceutical Quality (OPQ) + Office of Process & Facilities (OPF) reviews CMfg facilities; PAI inspections include explicit CMfg elements + RTRT model verification. FDA’s Emerging Technology Program (since 2015) provides pre-IND through post-approval engagement specifically for novel manufacturing technologies.
- 2019 FDA Guidance: “Modernization of Pharmaceutical Manufacturing” (CDER strategic priority)
- 2024 FDA Final Guidance: “Quality Considerations for Continuous Manufacturing” (for drug substance + drug product)
EMA: CMfg-specific section in MAA dossier; PAT + QbD endorsed via 2014 + 2017 reflection papers. EMA Quality Innovation Group + EMA CMfg taskforce.
PMDA: Joint Japanese MHLW + PMDA CMfg roadmap 2020+; commercial CMfg applications approved.
Health Canada: PHARMA Initiative + continuous manufacturing taskforce; co-aligned to ICH Q13.
China NMPA: ICH member since 2017; QbD + PAT recognized; CMfg adoption gradually accelerating.
7.2 FDA Emerging Technology Program (ETP)
CDER (drug review) + CBER (biologics) + CDRH (devices) host ETP since 2014. Sponsors propose novel technology to ETP team early; FDA engages pre-NDA across development. Vertex’s continuous OSD program for Orkambi was the ETP-pathway exemplar (approval 2015).
ETP categories (FDA list ~2024):
- Continuous manufacturing
- 3D printing (drug + device)
- Single-use systems
- AI/ML applications
- Distributed/decentralized manufacturing
- Allogeneic cell therapy manufacturing
- mRNA + lipid nanoparticle platforms
7.3 Facility validation
- Equipment qualification — DQ + IQ + OQ + PQ
- Process validation — Stage 1 design, Stage 2 PQ at intended commercial state-of-control, Stage 3 continued process verification (CPV)
- Process Performance Qualification (PPQ) — typically 3 lots/runs at commercial scale; for CMfg, validated by extended run time
- Cleaning validation — risk-based per ASTM E3106 + EU GMP Annex 15
- Computer system validation (CSV) — GAMP 5 + Annex 11 + 21 CFR Part 11
- Periodic review — APR (Annual Product Review)
8. Facility design + utilities
A typical CMfg facility footprint:
| Area | Footprint (m²) | Notes |
|---|---|---|
| API train (reactors + crystallizers + filters + dryers) | 800-1,500 | Containment per OEB |
| Drug product train (granulator + dryer + tablet press + coater) | 600-1,200 | Containment + ISO 8 |
| Packaging + warehousing | 1,500-3,000 | Including secondary packaging + serialization |
| QC lab (PAT + stability + analytical) | 500-1,000 | Microbiology + chemistry + stability chambers |
| Utilities + tank farms (solvents, gases, WFI) | 1,500-3,000 | Closed transfer lines |
| HVAC + dust collection + waste | 800-1,500 | High-OEB containment |
| Admin + IT + locker rooms | 1,200-2,500 | |
| Total | 7,000-13,000 | Vs equivalent batch ~12,000-25,000 |
8.1 Containment + OEB
Occupational Exposure Bands (OEB) per ISPE — most APIs OEB 3-4 (1-30 µg/m³); some highly potent compounds OEB 5 (<1 µg/m³) require glove-box isolators + RABS (Restricted Access Barrier Systems) and rigorous personal protective equipment.
- Isolators — Skan Inox + ENVAIR + IsoTech + Howorth Air Tech + ChargePoint
- Closed transfer (split butterfly valves) — ChargePoint + Müller + GEA Buck + GEA Sanitech
- Continuous liners — ILC Dover + Hosokawa + Eltete + Müller for product transfer
- WIP (washing in place) + CIP (clean in place) + SIP (sterilization in place) systems
- HVAC + cascade pressurization — see batch-mfg analog design-pharma-fill-finish-line
8.2 Utilities
- WFI (Water for Injection) — pharmacopoeial pure water; multi-effect distillation (Stilmas + Pharmatec) or VC (vapor compression)
- Pure steam — generator + distribution loop
- Process gas — N₂, Ar, H₂, compressed air (oil-free), CO₂ — Atlas Copco + Ingersoll Rand + Linde + Air Liquide
- Solvent recovery — distillation + adsorption; Pope Scientific + Sulzer Chemtech + Koch-Glitsch packed columns; solvents (ACN, MeOH, IPA, DCM, THF) typically 70-90% recovered
- Waste handling — incineration + WWTP + biological treatment for aqueous waste
9. Cost build-up
9.1 Greenfield CMfg facility capex
| Item | Cost ($M) |
|---|---|
| Site + civil + shell | 25-45 |
| Process equipment (API train) | 25-50 |
| Process equipment (DP train, full ConsiGma + coater) | 15-30 |
| PAT + automation + DCS | 15-30 |
| HVAC + utilities (WFI + clean steam + gases) | 20-40 |
| Cleanroom + isolators + containment | 10-25 |
| Validation + qualification (DQ-IQ-OQ-PQ) | 8-15 |
| Engineering + design + project management | 15-30 |
| Contingency (15-20%) | 20-50 |
| Total CMfg greenfield | $150-315M |
Brownfield retrofit of an existing batch facility 30-50% of greenfield capex.
9.2 Opex per kg API (continuous vs batch)
| Cost element | Batch | Continuous | Delta |
|---|---|---|---|
| Direct labor | High | 40-60% reduction | -50% |
| Material (yield improvement 10-20%) | Baseline | Lower | -10 to -15% |
| Utilities (energy + water) | Baseline | 20-30% reduction | -25% |
| QA/QC + lab | High | 30-40% reduction (via RTRT) | -35% |
| Maintenance + facility depreciation | Baseline | Higher per-unit due to high capex | +10% |
| Total per-kg COGS | Baseline 100% | 50-70% of batch | -30 to -50% |
9.3 Time-to-market
- Process development: parallel TSWG + flow chemistry shortens by 6-12 mo vs batch
- Tech transfer + scale-up: “scale-out” by run-time eliminates scale-up campaigns
- Commercial launch: faster ramp + ability to throttle output to demand
10. Approved CMfg products (FDA, 2016-2024)
| Year | Product | Sponsor | Modality |
|---|---|---|---|
| 2016 | Prezista (darunavir) | Janssen | OSD, first CMfg approval |
| 2016 | Orkambi (lumacaftor/ivacaftor) | Vertex | OSD |
| 2017 | Verzenio (abemaciclib) | Eli Lilly | OSD |
| 2018 | Symdeko / Symkevi (tezacaftor/ivacaftor) | Vertex | OSD |
| 2018 | Daurismo (glasdegib) | Pfizer | OSD |
| 2018 | Symtuza (D/C/F/TAF) | Janssen | OSD |
| 2019 | Trikafta (elexacaftor/tezacaftor/ivacaftor) | Vertex | OSD |
| 2023+ | Multiple sNDAs converting batch products to continuous | Various | Brownfield post-approval changes |
Pipeline 2025-2028: 15-25 additional sNDAs converting from batch + new NDAs filing with CMfg from launch are in CDER OPF queues.
11. Risk register
- Regulatory variability — Q13 was finalized 2023 but jurisdiction-specific interpretations still emerging; pre-approval engagement essential
- PAT model drift — multivariate models may degrade as raw material variability shifts; lifecycle model maintenance program required
- Tech transfer risk — first-of-a-kind facilities face longer-than-expected commissioning + qualification
- Equipment availability — twin-screw granulators + integrated CMfg lines have lead times of 12-24 months from GEA + Glatt + IMA + Bosch
- Workforce — operators trained on continuous process flow + process engineers familiar with PAT + multivariate analytics in short supply
- Energy + utility resilience — continuous operations are intolerant of brief power/utility outages; UPS + redundant utilities required
- Raw material consistency — CMfg demands tighter raw material specifications than batch (no opportunity for compensating in-batch adjustment)
- Cybersecurity — DCS + PAT + MES are network-attached; ISA/IEC 62443 + 21 CFR Part 11 audit trails required
- Inspection findings (Form 483) — FDA + EMA inspectors with CMfg experience are limited; sponsor may face inconsistent inspection rigor
12. Adjacent
- design-pharma-fill-finish-line — the sterile injectables equivalent (parallel batch process for parenterals)
- design-fda-drug-approval-pipeline — the NDA/BLA pathway in which CMfg facility files
- design-crispr-clinical-lab — adjacent regulated cleanroom + closed-system manufacturing
- pharma-process-engineering — unit operations + scale-out + process intensification
- chemical-process-fundamentals — reactor kinetics + mass balance + separations
- green-chemistry-and-process-intensification — solvent reduction + atom economy alignment with CMfg
- medicinal-and-photo-chemistry — small-molecule API synthetic route design